Phase 1 Trial Demonstrates Multi-Target T-Cell Therapy Producing Durable Responses in DIPG and Relapsed Pediatric CNS Tumors

{"The Children's National-led study infused expanded, non-genetically engineered T cells into 18 patients after lymphodepletion. Manufacturing succeeded in 17 cases; the maximum tolerated dose was established without dose-limiting neurotoxicity or cytokine release syndrome exceeding grade 2. Intravenous delivery produced detectable T-cell infiltration at tumor sites on imaging and biopsy, bypassing the need for direct CNS injection.","Among 11 patients with DIPG or relapsed high-grade glioma, three remained progression-free beyond 24 months and two beyond 36 months, an outcome exceeding typical median survival of 9-11 months after relapse. Objective radiographic responses occurred in four patients. Heterogeneity was addressed by simultaneous targeting of three antigens expressed in >70% of pediatric brain tumors per prior proteomic datasets.","This result extends the CAR-T paradigm from CD19+ leukemias into solid tumors by showing that non-engineered, multi-specific T cells can traffic across the blood-brain barrier and persist without the severe neurotoxicity seen in some GD2-CAR trials. It aligns with emerging data from the NexTGen Cancer Grand Challenge consortium emphasizing antigen breadth over single-target potency.","Next steps require a multi-center phase 2 trial powered for progression-free survival at 12 months as primary endpoint, with mandatory correlative studies of antigen-loss escape and T-cell exhaustion markers to guide combination strategies."}